NewAmsterdam Pharma Company NV Overview
Latest P/E ratio for NewAmsterdam Pharma Company NV: -10.32 — see history and peer comparisons.
Get informed when a big investor buys or sells
+ Follow-10.32
The P/E ratio compares a company's stock price to its earnings per share. A lower P/E ratio may indicate that the stock is undervalued.
The latest P/E ratio for NAMS is -10.32. That is below the sector sector average of 35.6. Investors often review this figure alongside NewAmsterdam Pharma Company NV's historical trend and sector peers before judging valuation or financial health.
Against its sector companies, NAMS currently prints -10.32 for P/E ratio, while the sector average sits near 35.6. That is roughly 129.0% below the sector mean. Large gaps often invite a closer look at NewAmsterdam Pharma Company NV's growth, margins, and balance sheet.
A P/E ratio of -10.32 for NewAmsterdam Pharma Company NV is not 'good' or 'bad' on its own. Compare it with the peer average (35.6) and with NAMS's multi-year chart on this page. Persistently elevated multiples need growth or quality to justify them; depressed multiples need a catalyst or evidence the business is misunderstood.
After noting NAMS's P/E ratio (-10.32), review year-over-year change, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.
